Please ensure Javascript is enabled for purposes of website accessibility


Jun 4, 2014

Glaxo pays $105M in multistate settlement

GlaxoSmithKline Plc, the U.K.’s largest drugmaker, will pay $105 million to settle claims by California, New York and more than 40 other states that it illegally promoted asthma and antidepressant drugs.

Dec 17, 2013

Maryland to receive $15.5M from Glaxo over drug ads

Maryland has recovered $15 million from drug maker GlaxoSmithKline LLC to resolve allegations that the company engaged in improper marketing of the prescription drugs Avandia, Avandamet and Avandaryl, all of which are used to treat diabetes.

Oct 17, 2012

In-House Interrogatory

Should general counsels be indicted by the government in investigations into company practices?

Oct 3, 2012

In-House Interrogatory

What are the main reasons you would fire outside counsel or have fired outside counsel in the past?

Sep 6, 2012

Human Genome Sciences to cut 114 jobs in October

ROCKVILLE — Rockville-based Human Genome Sciences says it will be cutting 114 jobs. The company told state regulators that it was undergoing an internal restructuring that will lead to the cuts at the end of October. British drug maker GlaxoSmithKline announced in July that it was acquiring the longtime partner in a $3.6 billion deal. […]

Jul 26, 2012

Judge refuses to delay Glaxo-Human Genome deal

DOVER, Del. — A federal judge in Delaware has refused to issue a restraining order delaying the acquisition of Human Genome Sciences Inc. by GlaxoSmithKline. Two HGS shareholders had argued that the tender offer period should be extended beyond Friday’s deadline because Glaxo’s agreement last week to pay $14.25 a share represented a new deal […]

Jul 16, 2012

GlaxoSmithKline wins takeover bid for Human Genome

U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people with diabetes and heart disease. The two companies said Monday that GSK will pay $3.6 […]

Jul 11, 2012

In-House Interrogatory

It’s all about in-house education this week. Asked: Our weekly question to the In-House community Most law schools don’t have classes that specifically prepare attorneys for jobs as in-house counsels. And in today’s unsteady economy, more law students are thinking of going directly into in-house careers, a trend we reported among Maryland schools in May. […]

Jul 2, 2012

GlaxoSmithKline to pay $3 billion for health fraud

WASHINGTON — GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest health care fraud settlement in U.S. history, the Justice Department said Monday. Accompanying the criminal case was a civil settlement in which […]

Jun 18, 2012

High court says no overtime pay for drug sales reps

WASHINGTON — The Supreme Court has ruled that sales representatives for pharmaceutical companies do not qualify for overtime pay under federal law, a big victory for the drug industry. In a 5-4 decision Monday, the court’s conservative majority concluded that the roughly 90,000 people who try to persuade doctors to prescribe certain drugs to their […]

May 17, 2012

Human Genome Sciences enters talks with potential suitors

Human Genome Sciences Inc. entered into confidentiality agreements with “certain parties” and is providing an opportunity to engage in due diligence reviews, the Rockville-based company said Thursday. Its board of directors unanimously said shareholders should reject an “inadequate” $2.6 billion bid from British pharmaceutical giant GlaxoSmithKline plc. Glaxo said on May 9 it would commenc[...]

Apr 19, 2012

Human Genome rejects GlaxoSmithKline’s $2.59B bid

The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, we think it’s a fair offer,” said Lauren Migliore, an equity analyst with Chicago-based Morningstar. […]

Networking Calendar

Submit an entry for the business calendar